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Abstract: This review provides a summary of recent progress in the development of different nanoplatforms for the efficient synergistic effect between photodynamic therapy and chemotherapy. In
particular, this review focuses on various methods in which photosensitizers and chemotherapeutic
agents are co-delivered to the targeted tumor site. In many cases, the photosensitizers act as drug
carriers, but this review, also covers different types of appropriate nanocarriers that aid in the delivery
of photosensitizers to the tumor site. These nanocarriers include transition metal, silica and graphenebased materials, liposomes, dendrimers, polymers, metal–organic frameworks, nano emulsions, and
biologically derived nanocarriers. Many studies have demonstrated various benefits from using
these nanocarriers including enhanced water solubility, stability, longer circulation times, and higher
accumulation of therapeutic agents/photosensitizers at tumor sites. This review also describes
novel approaches from different research groups that utilize various targeting strategies to increase
treatment efficacy through simultaneous photodynamic therapy and chemotherapy.

Pharmaceutics 2022, 14, 322.
https://doi.org/10.3390/
pharmaceutics14020322

Keywords: nano-platforms; nano photosensitizers; synergistic effect; combination of photodynamic
therapy/chemotherapy; drug delivery systems; cancer

Academic Editor: Maria
Nowakowska
Received: 23 December 2021
Accepted: 24 January 2022
Published: 29 January 2022
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affiliations.

Copyright: © 2022 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).

Pharmaceutics 2022, 14, 322. https://doi.org/10.3390/pharmaceutics14020322

https://www.mdpi.com/journal/pharmaceutics

Pharmaceutics 2022, 14, 322

2 of 40

Table of Contents
1. Introduction ........................................................................................................................................................................3
1.1. Principles of Photodynamic Therapy .........................................................................................................................3
1.2. Mechanism of Photodynamic Therapy ......................................................................................................................4
1.3. Photosensitizers ............................................................................................................................................................5
2. Combination of Photodynamic Therapy and Chemotherapy .....................................................................................5
2.1. Combination of Photosensitizers and Chemo-Drugs without External Carriers..................................................5
2.1.1. Photosensitizers as Carriers .............................................................................................................................5
MXenes..................................................................................................................................................................6
2.1.2. Photosensitizer-Drug Materials .......................................................................................................................9
2.2. Combination of Photosensitizers and Chemo-Drugs with External Carriers .......................................................9
2.2.1. Transition Metal Based Nano-Platforms .......................................................................................................12
Synthesis Routes of Transition Metals Nano-Platforms.................................................................................12
Application of Transition Metals in PDT.........................................................................................................13
2.2.2. Silica ..................................................................................................................................................................14
Synthesis Routes of Silica..................................................................................................................................15
Application of Silica in PDT..............................................................................................................................15
2.2.3. Graphene ..........................................................................................................................................................16
Application of Graphene in PDT......................................................................................................................17
2.2.4. Liposomes ........................................................................................................................................................18
Synthesis Routes of Liposomes........................................................................................................................19
Application of Liposome in PDT......................................................................................................................19
2.2.5. Dendrimers ......................................................................................................................................................20
2.2.6. Polymers ..........................................................................................................................................................20
Application of Dendrimers in PDT..................................................................................................................20
2.2.7. Metal-Organic Frameworks ...........................................................................................................................20
Main Synthesizing Methods.............................................................................................................................20
Application of Polymers in PDT......................................................................................................................20
2.2.8. Biological Nanocarriers .................................................................................................................................24
Preparation Method of Metal–Organic Frameworks....................................................................................24
Application of Metal–Organic Frameworks in PDT......................................................................................24
2.2.9. Nanoemulsions ...............................................................................................................................................25
Preparation of Red Blood Cells Membranes-Derived Vesicles....................................................................25
Application of Biological Nanocarriers in PDT.............................................................................................25
2.2.10. Nano Emulsions............................................................................................................................................26
Synthesis Routes of Nano Emulsions..............................................................................................................26
Application of Nano Emulsion in PDT...........................................................................................................26
2.3. Targeting Strategy......................................................................................................................................................26
2.3.1. pH Triggered...................................................................................................................................................27
2.3.2. Enzyme Triggered...........................................................................................................................................28
2.3.3. Redox Triggered Agents.................................................................................................................................28
2.3.4. Chemical and Biological Targeting Agents...................................................................................................29
3. Conclusions and Outlook ..............................................................................................................................................30
1. Introduction
In 2019, 1,762,450 new cancer cases and 606,880 cancer deaths were projected to occur
in the United States alone [1]. Common treatment strategies utilized to treat various cancers
include surgery, radiotherapy, and chemotherapy, which can be invasive and result in
serious short- and/or long-term side effects [2]. For instance, the mechanism-of-action in
many traditional chemotherapeutics interferes with cell division and is often associated
with severe systemic adverse effects such as myelosuppression, mucositis, alopecia, and
others. Other therapeutic options have their own drawbacks. Surgical resection of certain
tumors results in a high recurrence rate. Radiation therapy can be effective, but the cumulative radiation dose puts a hard limit on radiotherapy [3–5]. Due to the complicated
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burdens that these treatments can have on patients, new protocols and technologies are
needed to improve treatment options and patient outcomes [6]. Photodynamic therapy
(PDT) is one of these new promising approaches [7]. PDT is a treatment that involves the
delivery of a photosensitizer (PS) through topical or other systemic options and is followed
by irradiating the targeted tissue with a specific wavelength of light that is tailored to the
given photosensitizer [8]. Among the various types of photosensitizers, those that can
absorb visible or infrared light are more favorable due to the lower toxicity of infrared in
comparison with ultraviolet light. PDT can also be used before, after, or in combination
with more traditional treatment strategies. One advantage of many PSs is that they do not
accumulate in the nuclei of the cells, preventing them from being carcinogenic by themselves [6]. Furthermore, it significantly reduces side effects traditionally observed when
compared to chemotherapy or radiotherapy [9]. However, its efficacy against metastatic
cancers vs. primary tumors is still questionable as it requires light irradiation, and thus the
location of any secondary tumors must be known to be effective [10].
Some studies have recently investigated the efficacy of combining chemotherapy and
PDT [11]. For example, different in vitro studies have shown that the combination of photosensitizer with chemotherapeutic agents such as meso-tetrahydroxyphenylchlorine and
cisplatin were more effective than either therapy alone [12–14]. Therefore, in this review,
recent advances in the combination of photodynamic therapy and chemotherapy are covered.
1.1. Principles of Photodynamic Therapy
In 1903, von Tappeiner and Jesionek proposed the first published report on the use of
PDT as a treatment for skin tumors by using tropical eosin and exposing it to light [15,16].
They observed that oxygen was a significant part of the events found by Raab and co-workers,
and introduced the term “photodynamic action”. Research on using PDT as a treatment for
different tumors continued into the 1950s and 1960s by some research groups [17]. In these
reports, PDT had a great advantage compared to conventional therapies as they demonstrated
that they could limit toxicity to the tumor site, therefore protecting healthy cells to reduce off
target effects. Since then, PDT has been applied to the treatment of non-malignant diseases
in the field of dermatology, ophthalmology, urology, immunology, etc. [18].
1.2. Mechanism of Photodynamic Therapy
In PDT, a photosensitizer should be excited by a specific wavelength of light that causes
two different types of reactions to occur: type I and type II photochemical reactions [19]. As
shown in Figure 1, a photosensitizer’s electrons can be excited from the ground state to the
excited singlet state via light, which can cause three different situations. First, the exited
electron can decay back to the ground state and emit fluorescence. Second, an intersystem
crossing can occur to form a triplet state that is more stable than the singlet state. This
triplet state can either decay back to the ground state via emitting phosphorescence or it
may interact with the environment to generate radicals.
Type I reactions occur where the triplet state forms radicals with biomolecules such
as lipid radicals that can further react with other biomolecules and then oxygen to form
reactive oxygen species (ROS) such as hydroxyl radicals and hydrogen peroxides. Additionally, these excited electrons can react directly with molecular oxygen to produce
the superoxide anion radical, which can form other ROS species [20]. Type II reactions
occur if the energy of the excited photosensitizer is transferred to a triplet oxygen in the
ground state to generate a singlet oxygen. Even though both reactions (I and II) can be
damaging to cells, it has been proposed that reaction type II may be more important in vivo
for PDT. There are a large number of biomolecules such as proteins, lipids, and nucleic
acids that react with radicals generated by PDT. This phenomenon damages biomolecules
and subsequently damages tumor cells so that necrosis, apoptosis, or autophagy occurs.
Additionally, immune responses against tumor cells may be activated by PDT-induced
vascular injury [21–23]. Furthermore, chemotherapy can help PDT to be more efficient.
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2. Combination of Photodynamic Therapy and Chemotherapy
There are three different types of photosensitizers, which are presented in Table 1.
Photosensitizers can be utilized as carriers to deliver various types of therapeutics to
the targeted site. Therapeutics may be conjugated via chemical bonds or adsorbed to
the surface of the PS via van der Waals forces [27]. Some photosensitizers such as the
Ru(II) arene complex, [(η6-p-cymene)Ru(2,3-bis(2-pyridyl)-benzoquinoxaline)(pyridine)]2+ ,
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can act as a dual functional agent where these PS materials are both the photosensitizer
and the chemotherapeutic [28]. Additionally, drug delivery systems that have been referred to as third generation photosensitizers have been used to improve the efficiency of
photosensitizers such as enhancing the drug’s accumulation in the tumor site.
Table 1. Advantages and disadvantages of various nano-particles for cancer treatment.
Combination of PDT and
Chemotherapy
Without external carriers

Type of Carriers

Advantages

Disadvantages

Photosensitizers as carriers

1.
2.
3.

Faster synthesis process
Simple compound
Cost-effective

1.
2.
3.

Possible toxicity
Less-selectivity
Fast elimination

1.
2.
3.
4.
5.
6.

Biocompatible
Targeted drug carrier
Selective
Enhancing drug’s accumulation in the tumor site
Tissue penetration
Long time plasma half-life (stability)

1.
2.
3.
4.

Complex compound
Longer synthesis process
More cost
Complex elimination routes

Photosensitizer-drug materials
Transition metal based
nano-platforms
Silica
Graphene

With external carriers

Liposomes
Dendrimers
Polymers
Metal–organic frameworks
Biological nanocarriers
Nano emulsions

2.1. Combination of Photosensitizers and Chemo-Drugs without External Carriers
2.1.1. Photosensitizers as Carriers
Many photosensitizers have been reported as drug carriers (Table 2).
Table 2. Combination of photosensitizers and chemo-drugs without external carriers.
Reference

Photosensitizer (Carrier)

Drug

[27]
[28]
[29]
[30]
[31]
[32]
[33]
[34]
[35]
[36]
[37]
[38]
[39]
[40]
[40]
[41]
[42]
[43]
[44]
[45]
[46]
[47]
[48]

citric acid/CuS@Fe3 O4
[(η6-p-cymene)Ru(2,3-bis(2-pyridyl)-benzoquinoxaline)(pyridine)]2+
Porphyrin
Zinc phthalocyanine
Cyclometallated Ir(III) complex
Cu2−x Se
NaYF4:Yb/Tm-TiO2
Silver nanoparticles
ZnO nanorods
MnO2 -Pt@Au25
Zinc phthalocyanine
Polyelectrolytes-NaYF4:Yb/Tm
AgFeO2
MnFe2 O4
Cr2 Fe6 O12
Ti3 C2 MXene
Ti3 C2 MXene
MoS2
Boron-dipyrromethene
porphyrin-containing Janus macromolecular brush
mPEG-Hydrazone-Br2 -4,4-difluoro-4-bora-3a,4a-diaza-s-indacene
Ir(III)
Fe3 O4 @MnO2 -Chlorin-e6

Doxorubicin
Ru (II) segments
Oxaliplatin-adamantane
Coumarin
Camptothecin
Doxorubicin
Doxorubicin
Doxorubicin
Daunorubicin
Platinum (IV) prodrugs
Ganetespib
Doxorubicin
Quercetin
Curcumin
Curcumin
Doxorubicin
Metformin
Doxorubicin
Lenvatinib
Doxorubicin
Doxorubicin
Paclitaxel
Traditional Chinese medicine

For example, in 2019, Cui and co-workers [49] demonstrated a semiconducting polymer containing grafted polyethylene glycol. This polymer not only showed photodynamic
activity, but it was also a suitable carrier to conjugate other chemotherapeutic drugs such as
bromoisophosphoramide. This work was the first reported about hypoxia-activatable pho-
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totherapeutic polymeric prodrug systems. This is a semiconducting polymer nano-prodrug
(SPNpd) that can efficiently generate singlet oxygen (1 O2 ) under near-infrared (NIR) photoirradiation and activate its chemotherapeutic action in a hypoxic tumor microenvironment.
Lim and coworkers also [29] reported a nanocarrier that formed via host–guest interaction between oxaliplatin-adamantane prodrug and porphyrin as a photosensitizer to
achieve stimulus-responsive combination therapy [50]. Oxaliplatin and porphyrin were
separately modified with β-cyclodextrin and adamantane to synthesize the amphiphilic
host−guest system for self-assembly into therapeutic nanoparticles. This redox-responsive
system aids oxaliplatin-adamantane to be inactive until it accumulates in tumor cells. This
phenomena can decrease the side effects on healthy cells.
MXenes
MXenes are a relatively new class of two dimensional (2D) materials that consist
of transition metals (M) and carbides, nitrides, or carbonitrides (X). The chemical formula of MXenes is Mn+1 Xn TX (n = 1, 2, or 3), where M is an early transition metal
(e.g., Ti, Mo, Cr, Zr, Sc, V, Ta, Nb or Hf), X is carbon and/or nitrogen, and TX stands
for the terminal functional groups (e.g., = O, OH, and F) found on the surface of MXene
flakes [51–54]. The type and ratio of functional groups depends on the preparation method,
post-synthesis steps, and the storage conditions of MXenes. The terminal functional groups
with hydrophilic nature endow MXenes with highly hydrophilic properties. Several unique
properties such as their excellent conductivity, impressive mechanical properties, and good
thermal conductivity makes MXenes highly suited for various applications such as electrochemical energy storage, water purification, electrocatalysis, optoelectronics, biomedicine,
and sensors [55–58].
Certain properties of MXenes make them more suitable for biomedical applications
compared to other 2D nanomaterials. The hydrophilic nature of MXenes, due to the functional groups on the surface, enhances their dispersibility in biological samples. Additionally, the planar 2D structure of MXenes endows them with a very high surface-to-volume
ratio, providing abundant sites for attaching various molecules such as therapeutics, targeting moieties, and other surface modification to improve biocompatibility. Dai and
coworkers [59] synthesized MnOx /Ti3 C2 composites through a simple redox reaction of
KMnO4 (a strong oxidizing agent), which can react with OH groups on the surface of
Ti3 C2 nanosheets and generates paramagnetic MnOX species simultaneously. Further
modification with soybean phospholipids (SP) enhanced both the stability of MnOx /Ti3 C2
composite nanosheets, but more importantly, the photo-thermal-conversion performance
for killing tumor cells via PTT. Moreover, MnOx /Ti3 C2 nanocomposites demonstrated
high biocompatibility, which broadens the potential biomedical applications that surface
modified MXenes could be used for. In addition, Liu and coworkers [60] (Figure 2) reported
Ti3 C2 -IONPs MXene composites synthesized by in situ growth of superparamagnetic
Fe3 O4 nanocrystals on the surface of Ti3 C2 MXenes. This composite exhibited a higher
photo-thermal conversion efficiency than bare Ti3 C2 . It also showed high biocompatibility
in vitro and in vivo without causing observable toxicity to cells and mice. MXenes also
have strong optical absorption in both first and second NIR (NIR-I and NIR-II) biological
windows [61,62], and they exhibit high photo-thermal conversion efficiency, providing
potential applications of MXenes for photoacoustic imaging (PAI) and cancer phototherapy
(both PDT and photo thermal therapy).
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Figure 2. Exfoliation process and surface engineering of magnetic 2D Ti3 C2 -IONPs-SPs nanocomposites and their multifunctionalities for tumor theranostics. Photoacoustic imaging: PS, and iron oxide
nanoparticles: IONP. Reproduced with permission from [60], The Royal Society of Chemistry, 2018.

Preparation of MXenes: The outstanding properties and great potential applications
of MXenes have led researchers to explore novel synthesis methods of new MXenes [63–65].
More than 100 different MXenes have been studied theoretically by computational models,
and more than 30 different types have been produced and studied experimentally [66,67].
These compounds can be synthesized similar to other 2D materials via top–down and
bottom–up approaches. However, the top–down approach is generally used to synthesize MXenes in order to enable large-scale production and minimize costs. MXenes are
experimentally synthesized by selectively etching the “A” element from the MAX phase
that has the chemical formula Mn+1 A Xn , where M is a transition metal, A is an A-group
(group 13–16) element, and X is carbon and/or nitrogen [68]. MAX phases are composed
of A layers sandwiched between hexagonal transition metal carbides and nitrides. Although the strength of bond between elements M and A is weaker than between elements
M and X, mechanical exfoliation cannot break the metallic bonds of M–A and requires
etching away the A layers with F containing etchants such as hydrofluoric acid (HF), a
mixture of hydrochloric acid/lithium fluoride (HCl/LiF), or ammonium hydrogen bifluoride (NH4 HF2 ) [54,69–71]. During etching, the A layers are replaced by functional groups
such as OH, O, or F. The number and the types of functional groups on the surface of
MXenes heavily depend on the type of MAX phase, the type of etchant, and the synthesis
method [51]. In order to separate the layers of m-MXenes to single layer MXenes, the intercalation step is necessary by introducing large organic solvents such as dimethyl sulfoxide
(DMSO), tetrabutylammonium hydroxide (TBAOH), tetramethylammonium hydroxide
(TMAOH), and metal cations such as Li+ to increase the interlayer spacing and weaken the
interactions between layers [51,72,73]. After the intercalation step, sonication (bath or tip)
or hand shaking can delaminate the MXene sheets from each other [54].
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Application of MXenes in PDT: MXenes have been utilized for various anticancer
therapy applications. They have been used in many different modes such as nano-platforms
in drug delivery, photo-thermal agents for photo-thermal therapy, and as photosensitizers
(ROS generation) for PDT [66,74]. Liu and co-workers [41] reported the reactive oxygen
species (ROS) generation capabilities of Ti3 C2 MXene nanosheets under irradiation. They
developed a surface modification method to synthesize a small lateral size of Ti3 C2 MXene
nanosheets with functional groups of Al(OH)4 − by supplying additive Al3+ during the
etching step. This new composition exhibited an excellent mass extinction coefficient
(28.6 Lg−1 cm−1 at 808 nm) and outstanding photo-thermal conversion (∼ 58.3%) at 808 nm
laser irradiation due to the enhanced localized surface plasmon resonance (LSPR) effect.
These modifications also produced a negatively charged surface on the Ti3 C2 nanosheets.
They used this feature to utilize the layer-by-layer adsorption method to load doxorubicin
on the surface of the Ti3 C2 nanosheets and hyaluronic acid as the active tumor targeting
agent. Additionally, this modification enhanced the synergistic PDT/photo thermal therapy/chemotherapy by killing cancer cells in both in vitro and in vivo experiments [41].
In another study, Bai and co-workers [42] synthesized a multifunctional Ti3 C2 MXene
(Ti3 C2 @Met@CP) via layer-by-layer adsorption of metformin (Met) as a antitumor drug
and compound polysaccharide (CP) on the surface of the Ti3 C2 nanosheet, which resulted
in a high loading capacity of Met and CP. After the preparation of (AlOH)4 − functionalized
ultrathin Ti3 C2 nanosheets, Met was loaded on the surface of Ti3 C2 as a chemotherapy
drug to increase the adjuvant treatment. Then, to improve biocompatibility and endow
and activate immune function, CP was loaded on the surface of the Ti3 C2 @Met composite
nanosheet. A mixture of lentinan, pachymaran, and tremella polysaccharide in an optimal
ratio was mixed and called CP, showing better anticancer and activating immune function
effects than a single polysaccharide. The CP shell also effectively prevents the release of
Met in the process of blood circulation. In vivo and in vitro experiments demonstrated that
Ti3 C2 composite nanosheets have excellent stability, which enhanced the effective ablation
of tumors. In parallel, the photodynamic behavior of Ti3 C2 composite nanosheets was
investigated using DPBF and 20 , 70 -dicholofluorscein diacetate (DCFH-DA) as a detector for
in vivo and in vitro, respectively, showing the potential of Ti3 C2 composite nanosheets as a
new PS and to generate ROS upon 808 nm irradiation for PDT. Therefore, both in vitro and
in vivo experiments have shown that Ti3 C2 @Met@CP composite nanosheets not only have
an excellent synergistic therapeutic effect of PDT, photo-thermal therapy, and chemotherapy,
but also have the ability to activate the immune system. This feature caused the complete
eradication of the tumor and inhibited tumor recurrence and metastasis. The mechanism
of 1 O2 formation in Ti3 C2 (Ti3 C2 @Met@CP and Ti3 C2 -DOX) involves the transfer of the
energy of photo-excited electrons from Ti3 C2 to 3 O2 . The exact mechanism is currently
unknown with most published papers focusing on the application of MXenes in photo
thermal therapy, of which there are currently only a few.
2.1.2. Photosensitizer-Drug Materials
Chen and co-workers [28] developed the Ru(II) arene complex, [(η6-p-cymene)Ru(2,3bis(2-pyridyl)-benzoquinoxaline)(pyridine)]2+ , which is able to generate 1 O2 , and its ligand
can be dissociated under irradiation with visible light to demonstrate dual potential for
PDT and photoactivated chemotherapy (Table 2). The distorted coordination geometry of
2,3-bis(2-pyridyl)-benzoquinoxaline, which is due to its bulky nature, assists Ru to be more
exposable to fragment nucleic bases of DNA. In 2018, Yang and co-workers [36] introduced
a novel biodegradable photosensitizer formulated as MnO2 -Pt@Au25 for dual PDT and
chemotherapy. In this nano-platform, manganese oxide can react with glutathione, whereby
it can improve the efficiency of PDT (Figure 3).
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Table 3. Combination of photosensitizers and chemo-drugs with carriers.
Reference
[75]
[76]
[77]

Photosensitizer

Drug

Carrier

Photochlor
Merocyanine 540
Mitoxantrone

Prodrug banoxantrone
Doxorubicin
Mitoxantrone

UiO-66-H/N3 (MOF)
YbPO4 :Er, Dy
PEGylated Hollow gold nanoparticles
Gd-up conversion nanoparticles
core/mesoporous silica shell
Micelles
NaGdF4 :Yb/Nd@NaGdF4 :Yb/Er@NaGdF4
NaYF4:Yb/Tm/Er
NaYF4:Yb/Er
Up-conversion nanoparticles
Up-conversion nanoparticles
[Mg(1−x) Alx (OH)2 ][An− x/n ]·zH2 O
Mesoporous silica nanoparticle
Polyethylene glycol
Mesoporous silica nanoparticle
Hollow Mesoporous Silica
Mesoporous silica nanoparticle
Mesoporous silica nanoparticle
Fe3 O4 @mSiO2 (DOX)@ Human serum albumin
Mesoporous hollow silica
Mesoporous silica nanoparticle

[78]

Hematoporphyrin

Docetaxel

[79]
[80]
[81]
[82]
[83]
[84]
[85]
[86]
[87]
[88]
[89]
[90]
[91]
[92]
[93]
[94]

Camptothecin-11
Platinum IV
AB3 , a histone deacetylase inhibitor
Doxorubicin
Camptothecin
Doxorubicin
c,c,t-[Diamine-dichlorodisuccinato-platinum(IV)]
Doxorubicin
Doxorubicin
Doxorubicin
Doxorubicin
Cisplatin
Doxorubicin
Doxorubicin
Doxorubicin
Cisplatin

[96]
[97]
[98]

Chlorin core star shaped block copolymer
Rose Bengal
Rose Bengal
Merocyanine 540
Chlorin-e6
Pyropheophorbide
Chlorin-e6
Zinc(II) phthalocyanine
Chlorin-e6
Chlorin-e6
Hematoporphyrin
Aluminum chloride phthalocyanine
PEGylated tetraphenylporphyrin zinc
Chlorin-e6
Fullerene (C60)
Chlorin-e6
2-[1-Hexyloxyethyl]-2-devinyl
pyropheophorbide
Chlorin-e6
Indocyanine green-octadecylamine
IR780

[99]

Porphyrin

Doxorubicin

[100]

5,10,15,20-Tetraphenylchlorin

Paclitaxel

[101]
[102]
[6]
[103]
[104]
[105]
[106]
[107]

Chlorin-e6
Indocyanine green
Chloroaluminum phthalocyanine
CaFe2 O4
Hypocrellin A
MnO2
4-Hydroxy coumarin
Methylene blue

Doxorubicin
Doxorubicin
Doxorubicin
Curcumin
7-ethyl-10-hydroxycamptothecin
Cis-Platine
Camptothecin
Doxorubicin

[108]

Zinc(II) phthalocyanine

Doxorubicin

[109]

Hematoporphyrin

Doxorubicin

[110]

NIR dye-IR820

Docetaxel

[95]

Doxorubicin

Liposome

Doxorubicin
Doxorubicin
Tirapazamine

Microbubble-lipid mixture
Light sensitive liposome
Liposome
Dendritic poly(ethylene glycol) (PEG-G3-OH)
copolymer
Red blood cells membrane-camouflaged
nanoparticles
Hybrid protein oxygen carriers
Red blood cells containing oxyhemoglobin
Nano emulsions
Polyvinyl alcohol
Graphene oxide
Graphene oxide
Graphene oxide
Graphene oxide
Methoxypolyethylene glycol (mPEG) and
poly(β-benzyl-L-aspartate)
Co-polymer containing arylboronic ester
(BE)-modified with amphiphilic co-polymer
(mPEG-PBAM).
Methoxy-poly ethylene glycol-poly caprolactone
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Table 3. Cont.
Reference

Photosensitizer

Drug

Carrier

[111]

Pyrolipid

Oxaliplatin

[112]

4,4-difluoro-4-bora-3a,4a-diaza-sindacene

Doxorubicin

[113]

Fluorogen photosensitizer

Paclitaxel

[114]

Hematoporphyrin

Doxorubicin

[115]

NIR fluorophore

Paclitaxel

[116]

Hyaluronic Acid-chlorin-e6

Tirapazamine

[117]

Zn

Docetaxel

[118]

5-aminolevulinic acid

Doxorubicin

[119]

Mesotetra(p-hydroxyphenyl) porphine

Cis-platinum

[120]
[121]

Chlorin-e6
C60

Doxorubicin
Doxorubicin

[122]

Chlorin-e6

Doxorubicin

[123]

Merocyanine 540

Doxorubicin

[124]

Pyropheophorbide-a

gemcitabine

[125]

Zinc phthalocyanine

Doxorubicin

[126]
[127]
[128]
[129]

Indocyanine green
Purpurin 18
Gold nanoclusters
protoporphyrin IX

Doxorubicin
Doxorubicin
Doxorubicin
Doxorubicin

[130]

Chlorin-e6

Tirapazamine

[131]

Chlorin-e6

Gambogic acid

[132]

Si photosensitizer

Doxorubicin

[133]

Chlorin-e6

Doxorubicin

[134]
[135]
[136]
[137]
[138]
[139]
[140]
[141]
[142]
[143]

Pyropheophorbide
Pheophorbide a
Chlorin-e6
Chlorin-e6
porphyrin
Chlorin-e6
Chlorin-e6
Chlorin-e6
Chlorin-e6
pyropheophorbide-a

paclitaxel
Tirapazamine
Doxorubicin
Oridonin
Doxorubicin
Gemcitabine
Gemcitabine
Paclitaxel
Docetaxel
camptothecin

[144]

Chlorin-e6

Doxorubicin

[145]

Chlorin-e6

Perfluorohexanoate-modified cisplatin

[146]
[147]
[148]
[149]

protoporphyrin IX
zinc phthalocyanine
Chlorin-e6
Porphyrin
5-aminolevulinic acid to produce
protoporphyrin IX

Tegafur (prodrug of 5-fluorouracil)
Tirapazamine
cisplatin
Paclitaxel

1,2-distearoyl-sn-glycero-3-phosphocholine, cholesterol,
1,2-distearoyl-sn-glycero-3-phosphoethanolamine
polyethylene glycol 2000
mPEG-polyaspartic acid-benzaldehyde
Poly(ethylene
glycol)-b-poly(5-mthyl-5-propargyl-1,3-dioxan-2-one)
PEGylated (cyclo-arginine-glycine-aspartic
acid-d-phenylalanine-cysteine) peptide
Poly(ethylene
glycol)-b-poly(5-mthyl-5-propargyl-1,3-dioxan-2-one)
Self-assembling amphiphilic polyethylenimine-alkyl
nitroimidazole
Co-polymers poly(ethylene
oxide)-poly(ε-caprolactone)-poly(ethylene oxide)
Hydroxyethyl chitosan and aldehyde-functionalized
hyaluronic acid
Mesotetra(p-hydroxyphenyl)-Pt-PEG (covalent-organic
polymers)
Hyaluronic acid-chlorin-e6
C60–PEI–DOX
(ε-caprolactone-co-lactide)-b-poly (ethylene glycol)-b-poly
(ε-caprolactone-colactide)
UCNP-loaded (NaYF4 :Yb, Er) folate-conjugated polymeric
(dextran)
Human serum albumin
[methoxy-poly(ethylene
glycol)-poly(2-(N,N-diethylamino)ethyl
methacrylate)-poly(ε-caprolactone)]4-zinc β-tetra-(4-carboxyl
benzyloxyl)phthalocyani
Nano-scaled red blood cells
mPEG-Cyclodextrin-Polyhydroxybutyrate
(ZIF-8) metal–organic framework
(ZIF-8) metal–organic framework
(polyethylene glycol)-Azo-benzene-poly (d,
L -lactide-co-glycolide)
Hyaluronic acid-nitroimidazole (HA-NI) as shells, MnO2 NPs
functionalized poly (L-glutamic acid) derivatives (γ-PFGA)
as cores
Mesoporous silica nanoparticle
Polyoligo (ethylene glycol) methacrylate-block-poly(εcaprolactone)-azobenzene-poly(ε-caprolactone)-block-poly
oligo (ethylene glycol)
Poly [oligo (ethylene glycol) methyl ether methacrylate]
Self-assembled gelatin nanoparticles
Poly(phosphorylcholine)
Side-chain selenium-grafted polymers
Tetra-β-cyclodextrin
Polymeric micelles
Multifunctional polymeric prodrug micelles
Liposomes
Hyaluronic acid
mPEG with thioketal linker
Block copolymers polystyrene-b-poly (acrylic acid) and
oil-soluble
Poly(ethylene
glycol)-lysine-block-poly(L-glutamate)-imidazole
Heterodimers hydrogel
Hyaluronic acid
Dual-effect liposome
Porphyrin-lipid shelled nano-emulsion

Doxorubicin

Nanogel

[150]

2.2.1. Transition Metal Based Nano-Platforms
The most important materials that are used as both nanocarriers and photosensitizers
are prepared based on transition metals. Photosensitizer systems based on transition metals
have been significantly used due to their ability to be triggered by near infrared light,
which is less harmful than ultraviolet light for the human body and has a greater tissue
penetration depth. On the other hand, most nano-platforms have up-conversion ability,
which is the ability of emitting visible or ultraviolet light by absorbing near infrared [33].
Different transition metals such as Cr, Mn, Fe, Co, Ni, Cu, and Zn can be combined or
doped to make nano-platform systems that can decrease the energy gap of transition metals
to the range of visible and infrared light. Iron can combine with oxygen and a third metal
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to form one of the well-known metal nano-platforms. Spinel ferrites, which are shown by
10 of 42
the MFe2 O4 (M = the third metal) formula, usually with magnetic properties, are among
new types of hybrid materials that can be suitable platforms for several other applications
such as drug carriers and photosensitizers.
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Synthesis Routes of Transition Metals Nano-Platforms
Table
Combination
of photosensitizers
and chemo-drugs
carriers.
There3.are
several methods
for synthesizing
transition with
metal
nano-platforms. Among
Reference
[75]
[76]
[77]
[78]
[79]
[80]
[81]
[82]
[83]
[84]
[85]
[86]
[87]
[88]
[89]
[90]
[91]

them, hydrothermal, co-precipitation,
most common. Most
Photosensitizer
Drug and micro emulsion are the Carrier
of
these
methods
are
convenient,
environmentally
friendly,
and
inexpensive.
Photochlor
Prodrug banoxantrone
UiO-66-H/N3 (MOF)In the hydrothermal
method,
metal
salts
are
dissolved
in
water
and
heated
for 244:Er,Dy
h at about 100 ◦ C
Merocyanine 540
Doxorubicin
YbPO
in an oven. Then, the dried sample
is milled to form a PEGylated
powder. Finally,
is used
Mitoxantrone
Mitoxantrone
Hollowcalcination
gold nanoparticles
to crystallize the product [151]. In the coprecipitation method,
differentnanoparticles
metal ions are
Gd-up conversion
Hematoporphyrin
dissolved in water. Then, the Docetaxel
metal ion solution is added to
2 M NaOH (pH
14)shell
solution
core/mesoporous
silica
andshaped
stirred
for co30 min at 100 ◦ C. Finally, deionized water is used to wash the product
Chlorin core star
block
Camptothecin-11
Micelles
and decrease the pH to near 7 [152]. Additionally, in the micro emulsion method, two
polymer
organic
consisting
or anionic
species are4
4:Yb/Nd@NaGdF
4:Yb/Er@NaGdF
Rose
Bengal and inorganic phases
Platinum
IV of one or more
NaGdFcationic
added together. The AB
solution
is stirred
until inthe organic solvent has fully been removed.
3, a histone
deacetylase
Rose Bengal
NaYF4:Yb/Tm/Er
hibitor
The product is washed with water
and dried in vacuum. Finally, calcination is used to
Merocyanine
540 desired nano-platform
Doxorubicin
NaYF4:Yb/Er
obtain the
product.
Chlorin-e6
Camptothecin
Up-conversion nanoparticles
Application of Transition Metals
in PDT
Pyropheophorbide
Doxorubicin
Up-conversion nanoparticles
c,c,t-[DiamineDifferent nano-platforms
such as NaYF4 :Yb/Tm/Er [81] and NaYF4 :Yb/Er [82] are
x/n]·zHAi
2][An−Fujin
2O and
Chlorin-e6
dichlorodisuccinato[Mg(1−x)Alx(OH)
reported to have up-conversion
ability (Figure 5). For example,
in 2016,
platinum(IV)]
co-workers [80] assembled the
core–shell–shell biocompatible nano-platform NaGdF4 :Yb/
Zinc(II) phthalocyanine
Mesoporous silica nanoparticle
Nd@NaGdF4 :Yb/Er@NaGdFDoxorubicin
4 , which was loaded by platinum prodrugs [153]. This platChlorin-e6
Doxorubicin
glycol
form could be considered as up-conversion nanoparticles thatPolyethylene
are able to emit
ultraviolet
Chlorin-e6
Doxorubicin
Mesoporous silica nanoparticle
Hematoporphyrin
Doxorubicin
Hollow Mesoporous Silica
Aluminum chloride phthalocyanine
Cisplatin
Mesoporous silica nanoparticle
PEGylated tetraphenylporphyrin
Doxorubicin
Mesoporous silica nanoparticle

nation is used to obtain the desired nano-platform product.
Application of Transition Metals in PDT
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Figure 5. Targeted up-conversion nanoparticle-based micelles for simultaneous near infraredFigure 5. Targeted up-conversion nanoparticle-based micelles for simultaneous near infraredcontrolled combination chemotherapy and PDT. Polyethylene glycol: PEG, and poly(4,5controlled combination chemotherapy
and
PDT. Polyethylene
glycol:
and poly(4,5-dimethoxydimethoxy-2-nitrobenzyl
methacrylate):
PNBMA
(figure created
withPEG,
Inkscape).
2-nitrobenzyl methacrylate): PNBMA (figure created with Inkscape).

Transition metals are considered promising nanocarriers to deliver therapeutic
Transition metals are considered promising nanocarriers to deliver therapeutic agents
agents to cancer cells (Figure 6). In addition to their photosensitizing ability, they can alto cancer cells (Figure 6). In addition to their photosensitizing ability, they can also be
so be used as nanocarriers, which is very interesting for these types of materials. For exused as nanocarriers, which is very interesting for these types of materials. For example,
in 2011, Zhang and co-workers [35] prepared ZnO nano-rods containing daunorubicin as
an anti-cancer drug during a one-step solid state reaction under ambient temperature. It
was observed that the concentration of daunorubicin was significantly increased in human
hepatocarcinoma cells (SMMC-7721cells), which demonstrates that ZnO nano-rods are
not only good photosensitizers, but can also be considered as promising drug carriers for
daunorubicin [157]. In other projects, Zhang and co-workers [32] developed a Cu2−x Se
nano-platform for the treatment of malignant glioblastoma with near infrared PDT and
chemotherapy by using doxorubicin as an anticancer drug. Infrared absorption of Cu2−x Se
was around 1064 nm, and it was strong enough to penetrate deeply into the desired tissue.
It was also able to efficiently degrade H2 O2 and oxygen within the tumor to produce vast
amounts of reactive oxygen species [158,159]. Other research groups have also reported
nanoparticles that can be applied as both nanocarriers and photosensitizers such as citric
acid/CuS@Fe3 O4 [27], zinc(II) phthalocyanine [160], cyclometallated iridium (III) [31],
silver nanoparticles [34], and NaYF4:Yb/Tm [38] All nano-platforms demonstrated good
in vitro and in vivo therapeutic efficacy.
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used visible
light
irradiation
and oxidation/reduction
by which Ce
which
Ce
and
cisplatin
were
released
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the
layered
double
hydroxide.
and cisplatin were released from the layered double hydroxide.
2.2.2. Silica
Silica
2.2.2.
Different types
types of
of silica
silica nanoparticles
nanoparticles have
have been
been extremely
extremely widely
widely used
used in
in drug
drug dedeDifferent
livery
systems
[163,164]
due
to
their
biocompatibility,
high
surface
area,
high
stability,
livery systems [163,164] due to their biocompatibility, high surface area, high stability,
capability of
size.
These
abilities
make
mesoporous
capability
of surface
surfacemodification,
modification,and
andcontrollable
controllable
size.
These
abilities
make
mesoposilica a perfect nano-platform for a variety of therapies such as a combination of chemotherapy and PDT [165].
Synthesis Routes of Silica
In general, the following three methods are employed for the synthesis of solid silica
nanoparticles. Stöber’s method was discovered in 1968 and is among the most significantly
used methods for the preparation of silica nanoparticles. In this method, different types
of silicates such as tetraethoxysilane are mixed with ammonia, water, and ethanol to
synthesize the requested silica nanoparticles. The concentration of solvents and silica
additives can determine the size of the nanoparticles [166]. In the reverse micro-emulsion
method, the spherical micelles are formed by adding a surfactant to an organic solvent that
is transparent and thermodynamically stable. The preparation of silica nanoparticles occurs
in the interface of the micelles [167]. In the chemical vapor deposition method, which is
also called the high temperature flame decomposition method, precursors such as silicon
tetrachloride are brought into the vapor phase to be prepared for nucleation [168,169].
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Application of Silica in PDT
For example, in 2014, Fan and co-workers [78] successfully prepared a gadolinium/mesoporous silica core/shell nano structure to co-deliver hematoporphyrin and
docetaxel as the photosensitizer and chemotherapeutic agents. The nano-platform was
irradiated by near infrared and X-ray, which led to the complete elimination of the tumor
by the synergistic effect of chemo, radio, and photodynamic therapies [170]. Yang and
co-workers [88] prepared mesoporous silica nanoparticles that were doped by chlorin-e6.
The structure of the silica matrix was changed from sphere to rod-like shapes due to the
incorporation of chlorin-e6 into the matrix. This change was interesting because rod-like
mesoporous silica was more efficiently taken up by cells. In this study, doxorubicin was
utilized as the anti-cancer drug. In 2015, Yao and co-workers [91] synthesized mesoporous
silica nanoparticles that were modified by PEGylated tetraphenylporphyrin zinc using
the acid sensitive cis-aconitic anhydride bond. Silica pores can also be synthesized to
have a positive charge if the pH is around 6.8. Having a positive charge increases cellular
internalization, enhancing the efficacy of this nano-platform [171].
In 2018, Tang and co-workers [92] (Figure 7) successfully synthesized Fe3O4 @mSiO@human
serum albumin to act as a carrier for doxorubicin. They also used chlorin-e6 as the photosensitizer during this study. The nano-platform was irradiated by red light and utilized
for the treatment of glioma cells. In 2015, Yang and coworkers [93] prepared mesoporous
hollow silica-fullerene nanoparticles by the reverse micro-emulsion method. Doxorubicin
was encapsulated into the inner cavity, and fullerene was incorporated in the shell to
act as the photosensitizer. The ability of fullerene as a photosensitizer was increased in
mesoporous hollow silica because the pores that formed silica shells can increase the interaction between oxygen and fullerene to generate singlet oxygen more efficiently. In
2016, Zhang and co-workers [94] designed mesoporous silica nanoparticles to deliver the
chlorin-e6 photosensitizer and cisplatin prodrug to be used as a nano-platform for the
treatment of A549R lung cancer cells. Cisplatin prodrug was conjugated to silica by the
β-cyclodextrin-grafted polyethylenimine linker. The nano-platform was irradiated by red
light (660 nm), and it was observed to give a half-maximal inhibitory concentration (IC50 )
value was around 0.53 µM, which was much lower than that of cisplatin.
2.2.3. Graphene
Graphene is a 2D material that is an allotrope of carbon consisting of a single layer of
atoms arranged in a two-dimensional honeycomb lattice. Graphene has attracted tremendous research interest in recent years due to its exceptional properties. The scaled-up and
reliable production of graphene derivatives such as graphene oxide (GO) and reduced
graphene oxide (rGO) offer a wide range of possibilities to synthesize graphene-based
functional materials for various applications [172].
Tremendous efforts have been made to develop synthetic methods for graphene to
achieve high yields of production. Methods to make graphene can be generally classified
as bottom–up and top–down approaches. The bottom–up approach involves the direct
synthesis of graphene materials from carbon sources such as the chemical vapor deposition
(CVD) [173] or plasma enhanced CVD (PECVD) [174]. In comparison with the bottom–up
approaches, the top–down approaches are advantageous in terms of high yields, solutionbased process ability, and ease of implementation, which have been demonstrated by means
of intercalation, chemical functionalization, and/or sonication of bulk graphite. The first
observation of exfoliated graphite dates back to 1840 by Schafhaeutl, when H2 SO4 was used
for the intercalation [172]. Since then, a number of chemical species have been found to
form intercalated compounds with graphite [175,176]. Further attempts by combining the
intercalation and sonication have realized the isolation and dispersion of graphene sheets by
using intercalates such as N-methyl-pyrrolidone (NMP) [177] and sodium dodecylbenzene
sulfonate (SDBS) [178] in non-aqueous and aqueous solutions, respectively.
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In 2014, Jiang co-workers [104] used graphene oxide to deliver Hypocrellin A (photosensitizer). They observed that after loading of Hypocrellin A on graphene oxide, the
anticancer activity of Hypocrellin A was decreased. Therefore, they utilized 7-ethyl-10hydroxycamptothecin (SN-38) as the second chemotherapeutic agent to solve the problem. SN-38 was co-loaded on GO (Hypocrellin A/SN-38/GO) by hydrogen bond and
π–π
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stacking interaction to combine PDT and chemotherapy synergistically for an antiproliferative effect. In 2020, Zhou and co-workers [105] found a way to reduce tumor hypoxia
by the self-production of O2 and decrease intracellular GSH amounts to improve PDT
system
(TAM), whichThey
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the effect
of cyclophosphamide
(CTX)-loaded
2and
chemotherapy.
designed
a nanosheet
based
on MnO2-doped GO
to load CisPt
(1-hexyloxyethyl)-2-devinyl pyropheophor-bidealpha (HPPH)-coated PEG nano-graphene
and chlorin-e6 simultaneously. They found that, in addition to MnO2 ability to decomoxide [GO(HPPH)-PEG] by increasing its infiltration into tumors (670 nm, 70 J/cm2 ).
pose H2O2, it also decreases GSH levels in cancer cells (Figure 8).

Figure 8. Preparation routes of Go-CisPt-Ce6@MnO2. Graphene oxide: GO (figure created with
Figure 8. Preparation routes of Go-CisPt-Ce6@MnO2 . Graphene oxide: GO (figure created with Inkscape).
Inkscape).

2.2.4. Liposomes
In 2020, Vinothini and co-workers [106] decorated a reduced GO surface with magLiposomes have an aqueous solution core surrounded by a hydrophobic membrane in
netic nanoparticles as a new nano-platform that loaded with camptothecin (CPT) chethe form of a lipid bilayer; hydrophilic solutes dissolved in the core cannot readily pass
modrug
4-hydroxy
coumarin (4-HC)
photosensitizer
(365
laser irradiation
20
through and
the bilayer.
Hydrophobic
chemicals
associate with
thenm
bilayer.
A liposomeofcan
hence be loaded with hydrophobic and/or hydrophilic molecules. To deliver the molecules
to a site of action, the lipid bilayer can fuse with other bilayers such as the cell membrane,
thus delivering the liposome contents. Because of their structure as well as their high
loading capacity and ability to be modified, liposomes have been significantly used as
nanocarriers for different types of drugs. Their unique structure allows liposomes to be
accumulated in the tumor site efficiently and after modification, they can exhibit a long
time plasma half-life, which is important for tumor uptake. Hence, different types of pho-
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mW/cm2). The combined treatment indicated exceptional cell apoptosis and antitumor
activity. In 2019, Liang and co-workers [107] (Figure 9) fabricated a targeted nano system
(GO-Folate) with an ultrahigh surface area by Hummers’ method, which is loaded by
DOX and methylene blue (MB) via π−π stacking and hydrophobic or electrostatic interactions with high-load content. This nano-platform triggered DOX and MB release
by
17 of 40
heat and an acidic pH in tumor environments. In 2017, Zhao and co-workers [179] used
a macrophage transferring system (TAM), which effectively enhances the effect of cyclophosphamide (CTX)-loaded 2-(1-hexyloxyethyl)-2-devinyl pyropheophor-bidealpha
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agents canoxide
be loaded
into modified by
liposomes
simultaneously
(HPPH)-coated
nano-graphene
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PDT
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[180].
2
tion into tumors (670 nm, 70 J/cm ).
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sulated, at more than 50 C. Finally, liposomes can be created by complete evaporation of
the organic phase [183]. The freeze-thawed method uses multiple cycles of a rapidly frozen
and slowly thawed solution of liposomes, as the name implies. First, materials that are
used to prepare liposomes are separated by sonication for a short time. Then, the system
will be rapidly frozen and slowly thawed to allow for unilamellar vesicles to be fused and
created [184]. The extrusion method is another technique where the liposome suspension is
passed through a membrane filter of a defined pore size. An extruder, a machine equipped
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with a pump that pushes fluids through the membranes, can be employed to accomplish
the extrusion process. Various parameters of the extrusion procedure such as applied
pressure, number of cycles, and pore size have been found to influence the mean diameter
and size distribution (polydispersity) of the liposomes produced [185].
Application of Liposome in PDT
In 2003, Snyder and co-workers [95] used 2-[1-hexyloxyethyl]-2-vinyl pyropheophorbide as the photosensitizer and liposomally encapsulated doxorubicin as an anti-cancer
drug. The liposome was used for the treatment of murine colon 26 tumors, which showed
improvement in accumulation and selectivity due to enhanced vascular permeability by
liposome. In 2018, Lee and co-workers [96] encapsulated doxorubicin into human serum
albumin/chlorin-e6 as a photosensitizer into ultrasound-triggered microbubbles that were
prepared by different mixtures of lipids (DSPC: DSPE-PEG2k-NHS). The researchers used
sonoporation, which is the use of sound to modify the permeability of the cell membrane
during the treatment, to convert microbubbles to liposomes and enhance the efficiency of
PDT. This result revealed that doxorubicin and chlorin-e6 were delivered into the cells and
penetrated the tumor tissues with the aid of local ultrasound irradiation. Moreover, both
drugs can be delivered by sonoporation, and the mechanical effects of ultrasound irradiation into deep tumor sites where the drug has difficulty reaching from the bloodstream. In
2018, Li and co-workers [97] prepared a light sensitive liposome through the combination of
indocyanine green-octadecylamine and doxorubicin as the photosensitizer and chemotherapeutic agent. The surface of the liposome was functionalized by epidermal growth factor
receptor-2 (Her2) antibodies, and it was irradiated by near infrared light (808 nm) for the
treatment of MCF-7 breast cancer cell lines. In 2019, Yang and co-workers [98] encapsulated
lipophilic IR780 (photosensitizer) and hydrophilic tirapazamine (anti-cancer agent) into a
liposome for the treatment of hypoxic malignant tumor cells. The system was irradiated by
near infrared (808 nm) light. IR780 could generate a hypoxic microenvironment, which is
very suitable for tirapazamine to perform well and cause DNA double-strand breaks and
chromosome aberrations.
2.2.5. Dendrimers
Dendrimers consist of highly branched molecules that are designed three-dimensionally.
Examples include poly(propylene imine), polyesters, peptide dendrimers, triazine dendrimers, and polyamidoamine (PAMAM), which have great potential in biomedical applications due to their high loading efficiency and low toxicity [186–190]. Anti-cancer drugs
and photosensitizers can be encapsulated within the dendrimer or conjugated to surface
molecules such as acyl hydrazone or ester groups [191–193].
2.2.6. Preparation Methods of Dendrimers
There are two methods that are mainly used for the preparation of dendrimers termed
as the divergent and convergent methods. In the divergent method, the synthesis starts
with the core of the dendrimer and arms are added gradually to prepare the final desired
3-dimensional form of the desired dendrimer, and in the convergent method, the arms are
initially prepared and then subsequently attached to the core to create the desired final
form [194,195].
Application of Dendrimers in PDT
In 2016, Liu and co-workers [99] developed a dendritic poly(ethylene glycol) copolymer that was conjugated to porphyrin (photosensitizer) by a disulfide linker. Doxorubicin
was conjugated to the dendrimer utilizing the same disulfide linker to be glutathione responsive due to glutathione’s ability to reduce the disulfide bond. The nanocarriers showed
higher loading efficiency and cellular uptake than the linear co-polymer. The dendrimer
was irradiated by a visible light emitting diode (LED) to exhibit a great potential for PDT
and chemotherapy [179].
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2.2.7. Polymers
The ability of polymer micelles to self-assemble due to their amphiphilic nature have
gained much interest in drug delivery [196–201]. Self-assembled polymeric micelles exhibit
nano sized spherical structures, high thermodynamic stability, and biocompatibility.
As a new category of organic theranostic agents, semiconducting polymer nanoparticles (SPNs) have gained growing attention due to their diversified optical properties [202].
Moreover, structural modification of precursor polymers has led to SPN-based phototherapeutics. These agents are able to convert photo-energy to heat or reactive oxygen species
for PDT or photo thermal therapy [203,204].
Main Synthesizing Methods
Synthetic methods are generally divided into two categories: step-growth polymerization [205] and chain polymerization [206]. The essential difference between these two
processes is that in chain polymerization, monomers are added to the chain one at a time
only, whereas in step-growth polymerization, chains of monomers are combined with one
another directly. Step-growth polymerization can be further divided into polycondensation
and polyaddition [207,208].
Application of Polymers in PDT
In 2018, Gao and co-workers [108] developed a polymeric micelles (methoxypolyethylene glycol (mPEG) and poly(β-benzyl-L-aspartate) (PBLA)) encapsulating DOX (chemotherapeutic) and zinc(II) phthalocyanine (ZnPc) as the photosensitizers for dual therapy. Doxorubicin and ZnPc were conjugated to the polymer by an acid-labile hydrazone (pH sensitive) linker and a redox-responsive disulfide linker. Tests revealed that with increasing glutathione (GSH) levels, the disulfide linkers were cleaved and ZnPc moieties were released,
which diffused out from the dialysis membrane. In 2018, Li and co-workers [209] designed
stimuli-responsive nanoparticles based on an amphiphilic co-polymer containing arylboronic ester (BE)-modified with an amphiphilic co-polymer (mPEG-PBAM). The prepared
polymers formed micelles and were loaded with DOX and hematoporphyrin (Hp) [109] as
a PS (light irradiation: 635 nm, 5 mW/cm2 ). After irradiation, the BE part of the polymer
was cleaved due to ROS generation. ROS oxidizes the hydrophobic segment, making it
hydrophilic and destabilizing the structure. In 2016, Li and co-workers [110] investigated
micellar nanoparticles based on methoxy-poly ethylene glycol-poly caprolactone (mPEGPCL), which encapsulated docetaxel (DTX) [210] and NIR dye-IR820 (indocyanine green
derivative; irradiation: 808 nm, 2.5 W/cm2 ) for the synergistic therapy of breast cancer. In
2015, He and co-workers [211] reported a nano-micellar carrier based on a coordination
polymer (NCP) loading a high amount of cisplatin (25%), and phospholipid-porphyrin
(pyrolipid) was also used as a photosensitizer for combined therapy (irradiation at 670 nm
LED, 100 mW/cm−2 ). At sufficiently high pyrolipid loadings (when its lipid layers were intact), the fluorescence of pyrolipid molecules will self-quench due to their proximity to each
other. Therefore, Triton X-100 was added to the nano-platform to disrupt the lipid layer,
and NCP@pyrolipid could efficiently generate 1 O2 , which was confirmed by fluorescence
intensity (singlet oxygen sensor green). In 2016, Chunbai He and coworkers [111] evaluated
immunogenic nanoparticles to enhance the antitumor efficacy using a checkpoint inhibitor
such as antibodies to inhibit the PD-1/PD-L1 axis for colon cancer immunotherapy. This
nanoparticle is based on a NCP (1,2-distearoyl-sn-glycero-3-phosphocholine, cholesterol,
1,2-distearoyl-sn-glycero-3-phosphoethanolamine polyethylene glycol 2000) carrying oxaliplatin as a chemo-drug and the photosensitizer pyrolipid (irradiation at 670 nm LED, light
dose of 180 J·cm−2 given with 100 mWcm−2 ) for effective co-therapy that stimulated an
immune response.
In 2017, Zhu and co-workers [212] prepared an amphiphilic polyprodrug of poly(N,Ndimethylacrylamide-co-eosin)-b-poly camptothecin, which were assembled into hybrid
nanoparticles by oleic acid-stabilized NaYF4:Yb/Er to activate the eosin under a NIR
laser irradiation (980 nm laser, 1.5 W/cm2 ). In 2016, Ruan and co-workers [112] syn-
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thesized a pH-responsive polymeric micelle based on mPEG-PASP-benzaldehyde (PASP:
polyaspartic acid) conjugated with DOX and encapsulated with NIR photosensitizer 4,4difluoro-4-bora-3a,4a-diaza-sindacene (BODIPY) for both bioimaging and PDT (635 nm,
20 mW cm−2 ) [213]. BODIPY has many attractive properties such as high ratios of light–
dark toxicity and resistance to photobleaching. In 2018, Yi and co-workers [113] designed
a dual-delivery micelle based on amphiphilic polymeric prodrug poly(ethylene glycol)b-poly(5-mthyl-5-propargyl-1,3-dioxan-2-one)-g-paclitaxel (PMP) to load a red induced
emission fluorogen photosensitizer, TB (white light, 100 mW·cm−2 ), and a chemodrug, PTX
for synergistic PDT and chemotherapy. In 2018, Shi and co-workers [114] developed a PEGylated prodrug of DOX using thioketal linkage and cRGD (cyclo-arginine-glycine-aspartic
acid-d-phenylalanine-cysteine) peptide (RPTD) as a ROS-sensitive nanoparticle that was
encapsulated by the photosensitizer hematoporphyrin (HP) (633 nm at 100 mW/cm2 )
via π–π stacking interactions. The release of doxorubicin was ROS-responsive from the
prepared nanoparticles because of the break of the thioketal linker. In 2009, Peng and
co-workers [79] designed functionalized micelles based on a chlorin-core star-shaped
block co-polymer by a lyophilization–hydration method. This chlorin-core star-shaped
block co-polymer acts as a nano-photosensitizing agent (7 J/cm2 irradiation) by encapsulating a promising antitumor drug 7-ethyl-10-hydroxy-CPT (SN-38). In 2019, Zhen and
co-workers [115] reported a novel micelle based on the polymeric prodrug poly(ethylene
glycol)-b-poly(5-mthyl-5-propargyl-1,3-dioxan-2-one)-g-paclitaxel, which was loaded with
a NIR fluorophore as a photosensitizer that demonstrates a strong NIR emission for imaging applications and charge transfer properties for multidrug resistance tumor. In 2019,
Zhu and co-workers [116] prepared a PDT-induced hypoxia-responsive drug delivery
system by self-assembling amphiphilic polyethylenimine-alkyl nitroimidazole (PA) and
hyaluronic acid-chlorin-e6 (660 nm, 10 mW/cm2 ) to load tirapazamine (TPZ) as a bioreductive chemodrug [214]. TPZ can be changed to a toxic chemodrug via single-electron
reduction in hypoxic environments [215]. In 2013, Conte and co-workers [117] investigated a unique core-shell carrier with diblock (AB) and triblock (ABA) structures based on
amphiphilic block co-polymers poly(ε-caprolactone) (PCL = B) and poly(ethylene oxide)
(PEO = A) for co-delivery of the lipophilic chemodrug docetaxel (DTX), and the second
generation photosensitizer ZnPc (610 nm) by the melting/sonication method to treat an
animal model of orthotopic amelanotic melanoma.
In 2019, Cui and co-workers [49] designed semiconducting polymer nanoparticles
(SPNs) based on a light-responsive photodynamic backbone. The SPNs were grafted with
poly (ethylene glycol) (PEG) and conjugated with the chemodrug molecules via hypoxiacleavable linkers [216]. These SPNs efficiently produced 1O2 under NIR photo-irradiation and
activated its chemotherapeutic action in a hypoxic tumor environment, leading to cell death.
The layer-by-layer (LbL) assembly technique [217] is an effective way to produce
thin-film materials, which can control the configuration and specific functions of materials such as polymers using external stimuli. These kinds of blocks can be designed
into multilayer thin films by direct alternating deposition, or by employing the preassembly of building blocks. In particular, LbL films provide a useful platform for combining chemotherapy and PDT. For example, in 2016, Fan and co-workers [218] prepared
tellurium-containing photoresponsive polyelectrolyte multilayer films by LBL assembly of
a tellurium-containing two polymer. The polymers were (piperazine and PEG). They also
used indocyanine green (ICG) and porphyrin as photosensitizers and poly(styrenesulfonate)
as an anionic building block to make the film stronger and stable. The production of singlet
oxygen oxidizes tellurium to a high valence state (Te = O) on the polymer backbone, which
makes the micelles more hydrophilic, and facilitates the release of the loaded cargo from
the micelles. In 2018, Wang and co-workers [118] investigated unique multifunctional
polysaccharide-based nanoparticles by LbL self-assembly using hydroxyethyl chitosan
(HECS) and aldehyde-functionalized hyaluronic acid (AHA), which were stabilized through
Schiff’s base bond and electrostatic interactions. These particles were loaded with DOX
and pro-photosensitizer 5-aminolevulinic acid (635 nm light irradiation, 0.2 W).
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In the last decade, utilization of covalent-organic polymers (COPs) as therapeutic
agents [219] has received substantial attention in clinical fields. COPs can covalently
cross-link different types of organic molecules to form organic network configurations.
For example, in 2018, Wang and co-workers [119] evaluated a new class of COPs using
cross-linking of mesotetra(p-hydroxyphenyl) porphine (THPP) as a photosensitizer (using
a 660-nm LED light at a power density of 5 mW·cm−2 ) to a chemo pro-drug, cis-platinum
(Pt). Polyethylene glycol was conjugated to this pro-drug (THPP-Pt-PEG COPs) by the
one-pot reaction. THPP-Pt-PEG COPs could be stored in a lyophilized form and occur as
stable nanoparticles in aqueous solution. Upon intravenous injection, the COPs demonstrated long blood circulation time, tumor accumulation, and after injection of COPs into
mice, vascular perfusion and largely relieved tumor hypoxia, which are all favorable for
photodynamic treatment. In 2018, Wang and co-workers [220] presented a new type of
pH-responsive COPs by using acryloyl meso-tetra(p-hydroxyphenyl) porphine (acryloylTHPP) as a photosensitizer (660 nm, 5 mW·cm−2 ) and the pH-responsive crosslinked
biodegradable β-amino esters (BAEs), which are terminated by PEG shell (THPP-BAE-PEG
COPs). These COPs encapsulated DOX into their porous structure.
There are other nano-platforms that utilize polymers to make specific components or
encapsulate them in a proper shell. For example, in 2017, Wang and co-workers [221]
demonstrated an effective nanocarrier based on phospholipid/pluronic F68 complex
nanocores and pullulan (polysaccharide) shells to carry IR780 (a near-infrared dye) [222,223]
and paclitaxel (PTX) [224]. Additionally, pullulan acts as a natural ligand for the asialoglyco
protein receptor (ASGPR) [224], which is often overexpressed by HCC cells. In 2018, Liu
and co-workers [225] reported a light-responsive porphyrin-dextran-based polymeric DOX
conjugate to control DOX release through ROS-cleavable linker combined with PDT. In
2009, Khdair and co-workers [226] constructed aerosol OT (AOT)-alginate nanoparticles
for the co-delivery of DOX and methylene blue (a photo activated dye by 665 nm wavelength) in drug-resistant NCI/ADR-RES cells (a multidrug-resistant cell line in ovarian
cancer). In 2008, Hongrapipat and co-workers [227] evaluated the biological activities of
the anticancer drug SOS thiophene (SOS) and Mchlorin-e6 (650 nm at 3.0 mW/cm2 ) in the
form of Fab0 -targeted HPMA co-polymer-drug conjugates (Fab0 from OV-TL16 antibodies
matching to CD47) against OVCAR-3 cells, which indicated a very strong synergism. In
2016, Dong and co-workers [228] fabricated a DOX-loaded protein/polymer coated-up
conversion nanosystem including a UCN core (NaYF4:Yb/Er), folic acid-bovine serum
albumin−poly(ε-caprolactone) (FABSA-PCL) as an amphiphilic bioconjugate shell, and
ZnPc as a photosensitizer (980 nm laser at a power density of 1.0 W cm−2 ). In 2010, Khdair
and co-workers [226] improved the anticancer efficiency of DOX in combination with
the PS methylene blue (50 J/cm2 dose of non-coherent light at 665 nm) [229] in a tumor
model. These two drugs were encapsulated in surfactant-polymer hybrid nanoparticles,
which were synthesized by an anionic surfactant, aerosol-OT™ (AOT), and a polysaccharide polymer, sodium alginate. In 2019, Ren and co-workers [120] fabricated hyaluronic
acid-chlorin-e6 (DOX) as an enzyme/pH responsive nanoparticle. In this nanoparticle,
HA is combined with a highly effective photosensitizer (chlorin-e6) by adipicdihydrazide
(ADH) as a linker. Chlorin-e6 is a second generation photosensitizer that is able to be
activated by NIR light and is used for PDT [230]. In 2014, Shi and co-workers [121] synthesized a DOX-conjugated onto poly(ethyleneimine) (PEI)-fullerene (C60–PEI–DOX) to
facilitate photosynamic therapy and chemotherapy in one system as well as evaluate its
synergistic effect on cancer cells. C60 has been introduced as a nanocarbon material with
exceptional photochemical (532 nm laser, 100 mW·cm−2 ) and physical properties. They
used a hydrazone linker to make doxorubicin’s release pH sensitive. Compared with free
DOX in an in vivo murine tumor model, C60–PEI–DOX afforded higher antitumor efficacy
without obvious toxic effects to normal organs due to its good tumor targeting efficacy
and the 2.4-fold greater amount of DOX released in the tumor than in the normal tissues.
In 2018, Hu and co-workers [122] prepared oxygen-generating (CDM) nanoparticles by
assembling chlorin-e6 (660 nm, 100 mW/cm2 ), DOX, and manganese dioxide (MnO2 ) with
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poly (ε-caprolactone-co-lactide)-b-poly (ethylene glycol)-b-poly (ε-caprolactone-colactide)
for breast cancer therapy. MnO2 caused the breakdown of excessive endogenous H2 O2 to
produce O2 inside the tumors to relieve tumor hypoxia. With enhanced oxygen generation, the PDT effect was significantly improved under laser-irradiation. More importantly,
this effect, together with that of DOX, was able to dramatically promote the combined
chemotherapy-PDT efficacy of CDM NPs in an MCF-7 tumor-bearing mouse model.
In 2015, Wang and co-workers [123] prepared a new smart nanoparticle (pH-sensitive
and NIR light triggered) based on UCNP-loaded (NaYF4 :Yb, Er) folate-conjugated polymeric (dextran) lipid vesicles (UFPLVs) that carried DOX and merocyanine 540 (MC540)
as a photosensitizer (980 nm, 2.5 W cm−2 ). In 2017, Yu and co-workers [124] used human
serum albumin (HSA) as an effective nanodrug carrier for the delivery of gemcitabine
(Gem) and pyropheophorbide-a (670 nm light, 10 mW/cm2 ) for pancreatic cancer.
Albumin is a versatile protein with a unique structure that can be conjugated to hydrophobic and hydrophilic components [231,232]. In 2017, Zhang and co-workers [233] prepared a DOX-loaded magnetofluorescent carbon quantum dots (FeN@CQDs) into polymer
nanospheres (PEG) with magnetic and photoluminescent features using a low-cost and environmentally friendly one-pot hydrothermal method using iron crosslinked chitosan components (Ch-Fe-CL) [234]. Riboflavin (Rf) was grafted onto the surface of magnetic CQDs to be
useful in triggering PDT under NIR light, which significantly improved tissue penetration.
In 2017, Zhang and co-workers [125] fabricated a zinc phthalocyanine (8.12 mW/cm2 ) and
DOX-loaded pH-sensitive four-armed star co-polymer nanocarrier, [methoxy-poly(ethylene
glycol)-poly(2-(N,N-diethylamino)ethyl methacrylate)-poly(ε-caprolactone)]4-zinc β-tetra(4-carboxyl benzyloxyl)phthalocyanine (PDCZP) that showed better in vitro and in vivo
anticancer effects under lighting on MCF-7, SW480, and HepG2 cells and the murine
hepatocellular carcinoma H22 mode.
2.2.8. Metal–Organic Frameworks
Nanoscale metal organic frameworks are different types of hybrid porous nanomaterials that can be prepared by the coordinated interaction of metal ions and bridging ligands.
Metal–organic frameworks have great potential in drug delivery systems due to their
large surface area, high porosity, and modifiable surface chemistry [235]. Metal–organic
frameworks have also been used in PDT to provide a synergistic effect for cancer therapy.
For example, Zr6 clusters coordinated with terephthalic acid to form UiO-66, which has
microporous cages and excellent stability, so this UiO-66 can be considered as a suitable
candidate for drug loading [236,237].
Preparation Method of Metal–Organic Frameworks
In the solvo-thermal method, metal and organic precursors are added to an organic
solvent and are stirred at room temperature until a clear solution is formed. Then, the
homogenous mixture is transferred to a Teflon-lined autoclave and heated for 12 or 24 h.
Finally, the desired product is separated via centrifugation or filtration. These MOFs can be
modified by different organic ligands in the next levels [238,239].
Application of Metal–Organic Frameworks in PDT
In 2019, He and co-workers [75] designed UiO-66 metal–organic frameworks (UiO66-H/N3 NMOFs), and bioreductive banoxantrone (AQ4N), which was anchored to the
nanocarriers by a phosphate ion-sensitive bond. Photosensitizers such as photochlor
(HPPH) and azide were anchored to UiO-66 by the solvo-thermal method [240]. Moreover,
PEGylating was utilized to improve the stability of nanocarriers. The porosity of the
NPs is well-suited for the encapsulation of AQ4N to protect the bio-reductive prodrug
from degradation during circulation. In this system, AQ4N release is demonstrated to be
phosphate ion-sensitive. Both in vitro and in vivo studies revealed that the O2 -depleting
(consuming) PDT process does indeed aggravate intracellular/tumor hypoxia that activates
the cytotoxicity of AQ4N through a cascade process, consequently achieving PDT-induced
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and hypoxia-activated synergistic therapy. Benefiting from the localized therapeutic effect
of PDT and hypoxia-activated cytotoxicity of AQ4N, this hybrid nanomedicine exhibits
enhanced therapeutic efficacy with negligible systemic toxicity, making it a promising
candidate for cancer therapy. In 2020, Zhang and coworkers [128] (Figure 10) used ZIF-8
as metal–organic framework as a carrier to deliver Au and doxorubicin to achieve the
synergistic effect of photodynamic therapy and chemotherapy. Under irradiation with a
670 nm laser, a large amount of singlet oxygen was generated, and the release rate of DOX
increased to 77.1% at a pH value of 5.5. After using the combination therapy, all tumors
Pharmaceutics 2022, 14, x FOR PEER REVIEW
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were disappeared while single therapy could only inhibit tumors partially.
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were attached together by disulfide reconfiguration. Doxorubicin and chlorin-e6 were

Pharmaceutics 2022, 14, 322

24 of 40

which caused paclitaxel to be released [244]. In 2018, Luo and co-workers [101] introduced
hybrid protein oxygen carriers consisting of hemoglobin and albumin, which were attached
together by disulfide reconfiguration. Doxorubicin and chlorin-e6 were loaded into the
nano-hybrid. The ability of hemoglobin to carry oxygen provided a benefit in multiple
ways. This feature led to the downregulation of the expressions of multidrug resistance 1
(MDR1), hypoxia-inducible factor-1α (HIF-1α), and P-glycoprotein (P-gp), which further
breaks hypoxia-induced chemoresistance and interestingly helps chlorin-e6 to generate
more ROS. In 2017, Wan and co-workers [126] fabricated nano-scaled red blood cells consisting of oxyhemoglobin and the gas-generating agent ammonium bicarbonate to deliver
indocyanine green and doxorubicin as the photosensitizer and anti-cancer agent, respectively, for the treatment of breast cancer. After irradiation by 808 nm laser, oxyhemoglobin
decomposed into CO2 and NH3 , leading to the release of doxorubicin. It was observed that
this nanocarrier could facilitate breast cancer treatment and suppress metastases by the
combination of PDT and chemotherapy.
2.2.10. Nano Emulsions
Nano emulsions are thermodynamically stable nanoparticles whose size (20–200 nm)
and shape make them different from conventional emulsions. They consist of two immiscible liquids that are mixed by different types of surfactants.
Synthesis Routes of Nano Emulsions
There are several methods for the preparation of nano emulsions. However, all
methods can be classified into two main methods: high-energy emulsification such as
stirring, ultrasonic emulsification, high-pressure homogenization, micro-fluidization, and
low-energy emulsification such as phase inversion temperature, emulsion inversion point,
and spontaneous emulsification [245]. In the high-pressure homogenization method, a
high pressure homogenizer/piston homogenizer is used to prepare a nano-emulsion with
a particle size lower than one nanometer [246]. Additionally, in the micro-fluidization
method, a micro-fluidizer, which uses high pressure to produce a very fine particle with a
size range of 150–170 nm, is used. The process is a repeated procedure of forcing materials
to pass through the interaction chamber to prepare a uniform nano emulsion [247]. The
spontaneous emulsification method consists of three steps to prepare a nano emulsion. In
the first step, an organic solution containing the oil and surfactants is prepared. In the next
step, the organic phase is injected into the aqueous phase. Finally, the organic phase is
removed by evaporation to prepare a nano emulsion [248].
Application of Nano Emulsion in PDT
In 2018, Maria Candido and co-workers [6] prepared nano emulsions to encapsulate
hydrophobic chloroaluminum phthalocyanine as a photosensitizer and doxorubicin as
an anti-cancer agent. The nano emulsion was able to increase the water solubility of
chloroaluminum phthalocyanine, which was crucial to the efficiency of the drug delivery
system. Visible laser light was used to irradiate the nano emulsion, which caused the
photosensitizer to generate reactive oxygen species for the treatment of 4T1 breast cancer
cells. It was observed that the cell viability was less than 10% when a combination of
PDT and chemotherapy was applied. Therefore, this nano-platform can be considered
as a promising method of treatment for breast cancer [249,250]. In 2021, Chang and
coworkers [251] prepared porphyrin-lipid nano emulsions and loaded doxorubicin, PTX
(3.1 wt%), and porphyrin (18.3 wt%) efficiently into PLNE-PTX, forming spherical core–shell
nano emulsions. Combination therapy inhibited tumor growth (78%) in an additive manner
compared with monotherapy PDT (44%) or chemotherapy (46%) 16 days post-treatment.
2.3. Targeting Strategy
Various strategies such as pH triggered, enzyme triggered, chemical targeting agents,
biological targeting agents, and redox triggered agents have been used as targeting strate-
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gies to deliver drugs to a specific part of the body (Figure 11). Photosensitizers can be
loaded on nanocarriers and targeted to a specific tissue using these various means. These
targeting materials can be added to the nanocarriers to increase the accumulation and
efficiency
Pharmaceutics 2022, 14, x FOR PEER
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(pH = 6.8), the conjugated acid sensitive cis-aconitic anhydride bond between Zn and PEG
was cleaved and caused DOX to be released.
Ruan and co-workers [112] synthesized pH-responsive polymeric micelles based on
mPEG-PASP-benzaldehyde (PASP: polyaspartic acid), which is conjugated with DOX via a
hydrazone linker. In other work, Wang and co-workers [123] prepared a new intelligent
pH-sensitive nanoparticles based on UCNP (UFPLVs), which carried DOX by pH-sensitive
hydrazone bonds on the surfaces of the nanocarrier. In 2018, a new type of pH-responsive
COPs [220] was presented. In this study, acryloyl meso-tetra(p-hydroxyphenyl) porphine
(acryloyl-THPP) reacted with 4,40 -trimethylene dipiperidine (TMPD) to form pH-responsive
crosslinked biodegradable β-amino esters (BAEs) that can release DOX into the tumor
microenvironment.
2.3.2. Enzyme Triggered
Different cancerous cells upregulate the expression of certain enzymes on their surface
such as metalloproteinase and cathepsins. This phenomenon requires future studies to help
researchers develop novel targeting agents according to those upregulated enzymes [261].
Along this line, Zhu and co-workers [27] used co-acervation technology to prepare a
magnetic nanoparticle by gelatin and sodium alga acid. A citric acid/CuS@Fe3 O4 nanoplatform was prepared and DOX was loaded to be released by the enzymatic degradation
of gelatin by the presence of gelatinase. It was observed that this nano-platform not only
increased the accumulation of drugs in human breast cancer cells (MCF7), but also increased
the level of ROS production. In 2019, Cui and co-workers [49] designed a SPNs based on a
light-responsive backbone covered by PEG and conjugated with bromoisophosphoramide
mustard intermediate (IPM-Br) via hypoxia-cleavable linkers [216]. Hypoxia in cancer
cells precisely caused the fragmentation and release of IPM-Br catalyzed by nitroreductase,
leading to cell death.
2.3.3. Redox Triggered Agents
There are various reduction/oxidation (redox) reactions in cells, but cells continually
regulate ROS levels to maintain natural physiological baseline levels. However, when
cells turn cancerous, they alter their microenvironment, which can be exploited to develop
drug delivery systems. There are special microenvironments in cancerous cells. In these
cells, the level of glutathione and reactive oxygen species are higher than in healthy cells.
Therefore, according to the level of glutathione in tumor cells, redox responsive drug
delivery systems have been introduced to enhance the targeting ability of DDSs and
decrease the side effects of therapeutic agents [262]. For example, glutathione responsive
disulfide bonds were used to conjugate the anti-cancer agent camptothecin to iridium by
Xiang and co-workers [31]. Liu and co-workers [99] designed poly(ethylene glycol)-based
dendrimers (G3) that were conjugated to doxorubicin (anti-cancer drug) and porphyrin
(photosensitizer) via disulfide bonds and Yi and co-workers [113] prepared polymeric
prodrug poly(ethylene glycol)-b-poly(5-mthyl-5-propargyl-1,3-dioxan-2-one), which was
grafted to paclitaxel by the disulfide bond. These nano-platforms could release the drug
and photosensitizer by responding to the intracellular glutathione in cancer cells [263].
Platin prodrugs can also act as redox responsive materials. Their bond can be reduced
to facilitate the anti-cancer drug platin to be released. For example, Lim and co-workers and
Wang and co-workers used oxaliplatin prodrug cis-platinum to develop a redox responsive
nano-platform. Both groups observed that platin could be released only by changing the
levels of glutathione in tumor cells, which is very significant, in order to decrease the side
effects of highly toxic platin-based drugs [264]. In other research, Gao and co-workers [108]
developed polymeric micelles encapsulated with ZnPc as photosensitizers and DOX in
which ZnPc was conjugated to the polymer by a redox-responsive disulfide linker. In 2019,
Zhen and co-workers [115] reported a series of novel reduction-sensitive drug co-delivery
systems based on fluorophores with strong NIR emission.
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2.3.4. Chemical and Biological Targeting Agents
Targeting ligands can be conjugated on the surface of nanocarriers to enhance accumulation and selectivity for certain cells or tissue types. Different materials such as hyaluronic
acid, proteins/peptides, antibodies, carbohydrates/polysaccharides, aptamers, and folic
acid have been tested for their ability to improve the selectivity of drug delivery systems [265]. For example, in 2019, Liang and co-workers [107] fabricated a nano-platform for
synergistic effects based on GO to selectively deliver drugs into cancer cells that overexpress
folate receptors.
CD44 usually binds with hyaluronic acid, which is one of the main materials of
the extracellular matrix. Moreover, hyaluronic acid based materials can be degraded
by hyaluronidase, which is abundant in tumor cells [266,267]. In 2019, Ren and coworkers [120] conjugated hyaluronic acid to chlorin-e6 and DOX via adipic di-hydrazide as
a pH responsive linker. The result showed that the existence of hyaluronic acid could remarkably increase the cellular accumulation of DOX in A549 cells. In 2019, a new PDT-induced
DDS was introduced by Zhu and co-workers [116], which was made of polyethyleniminealkyl nitroimidazole (PA) and hyaluronic acid-chlorin-e6 to encapsulate TPZ. PA/hyaluronic
acid (chlorin-e6)@TPZ NPs were capable of accumulating in the tumor site effectively due
to hyaluronic acid-mediated cancer targeting. In another project, Zhou and co-workers [105]
designed a smart nanosystem based on GO and hyaluronic acid surface modifications to
improve and facilitate targeted delivery of CisPt and chlorin-e6 simultaneously.
Tumor homing peptides can be considered as other promising chemical targeting
agents, for example, Lyp-1, which has the p32 protein (HABP1 or C1QR protein) as its
receptor, can be conjugated to various drug delivery systems to increase their targeting
abilities. Lyp-1 has nine amino acids and its receptors are overexpressed on the surface
of cancer cell lines such as the 4T1, MDA-MB-435, and MCF-7 cell lines. Another peptide
that can be considered as the targeting agent is the KE108 peptide, a synthetic nanopeptide
that can efficiently target all five subtypes of somatostatin receptors overexpressed by
neuroendocrine tumor cells. For example, Li and co-workers [110] conjugated Lyp-1 to
cationic PCL grafted mPEG-PCL micelles, which were chosen as a carrier for docetaxel
and IR820 (photosensitizer). They chose the 4T1 cell line, and it was observed that the
presence of Lyp-1 could enhance the accumulation of micelles in the 4T1 cancer cell line,
which was further proven by the receptor saturation technique. In another project, Shi
and co-workers [114] developed a reactive oxygen species-responsive nanoparticle system
to combine PDT and chemotherapy for oral tongue squamous cell carcinoma. A PEGlated
prodrug of DOX via thioketal linkage and a peptide consist of cyclo-arginine-glycine-aspartic
acid-d-phenylalanine-cysteine was synthesized and then used to prepare nanoparticles for the
encapsulation of hematoporphyrin as the photosensitizer. In vivo experiments revealed that
the nanocarriers had great targeting ability due to both thioketal and the conjugated peptide.
Antibody-targeted nanocarriers for cancer therapy have an exceptional role because of
their specificity and vital advantages. Most monoclonal antibodies (mAbs) are used to target nanocarriers to cancer-specific antigens, deliver chemodrugs and photosensitizers in the
form of antibody–drug conjugates, and recruit cytotoxic T cells to combat cancer cells [268].
For instance, Shiah and co-workers [269] reported the combination therapy of HPMA
copolymer-bound DOX and Mchlorin-e6 targeted with an OV-TL16 mAb in OVCAR-3 carcinoma xenografts. The OV-TL 16 antibody can identify the OA-3 antigen, which is expressed
on OVCAR-3 cells and on most human ovarian carcinomas, and dramatically increased
the accumulation of nanocarriers in tumors. In 2008, Hongrapipat and co-workers [227]
confirmed increasing the biological activities of Fab0 -targeted HPMA copolymers (Fab0
from OV-TL16 antibodies matching to CD47) loaded with the anticancer drug SOS thiophene and Mchlorin-e6 over nontargeted conjugates. In 2018, Wang and co-workers [118]
investigated unique multifunctional polysaccharide-based nanoparticles [270] with the
anti-HER2 antibody as an active targeting agent [271] on the surface of the nanocarriers.
There are also other biological targeting agents. In 2016, He and co-workers [111]
fabricated the design of NCP nanoparticles that carried oxaliplatin and the photosensitizer

Pharmaceutics 2022, 14, 322

28 of 40

pyrolipid (NCP@pyrolipid) to significantly enhance antitumor immunity. NCP@pyrolipid
combines two therapeutic modalities, chemotherapy and PDT, to elicit antitumor immunity [272], as evidenced by early calreticulin (CRT) exposure on the cell surface, antitumor
vaccination, tumor-specific T-cell response, and an abscopal effect. The abscopal effect is
usually described with ionizing radiation and refers to regression of the tumor outside
the irradiated volume. Although the mechanism is unknown, it is thought to be immune
modulated. More importantly, NCP@pyrolipid PDT treatment in combination with PD-L1
checkpoint blockade therapy led to the regression of the primary tumors that were locally
treated with light irradiation and more interestingly, resulted in the regression of distant
tumors in bilateral syngeneic mouse tumor models of CT26 and MC38. It was shown
that this was achieved by generating a systemic tumor-specific T-cell response with the
infiltration of CD8+ T cells and CD4+ T cells in distant tumors.
3. Conclusions
In the present review, various types of photosensitizers, their synthetic strategies,
and the synergistic effect of PDT and chemotherapy were explored. This review split
photosensitizers into two main categories that can be defined as with or without external
carriers. In the first category, photosensitizers can act as either the drug or carrier, so
there is no need for external carriers or drugs to achieve the synergistic effect of PDT
and chemotherapy. In the second category, various external carriers such as transition
metals, silica, graphene, liposomes, dendrimers, polymers, metal–organic frameworks, and
different types of biological carriers are used to deliver photosensitizers and chemo–drugs
to specific tumor sites. Furthermore, there are other strategies to increase the efficiency of
treatment and decrease the side effects. For example, pH, redox, and enzyme triggered
methods and/or surface modification by different chemicals have been used to increase
the selectivity of photosensitizers and their carriers and potentially reduce or eliminate
unwanted side effects. Although lots of photosensitizers have been proven to be efficient,
the assessment of their cytotoxicity, biocompatibility, bio-distribution, and excretion are
very important and are currently under investigation. Finding more convenient ways
for treatment such as the oral administration of photosensitizers can further expand PDT
to gain even more attraction. Finally, the mechanism of cellular uptake and the fate of
different types of photosensitizers in the human body is key to their utilization. Appropriate
strategies and model systems are required to obtain comprehensive knowledge about such
complicated processes before using these materials in clinical trials. Eventually, we believe
that with all of these therapeutic strategies and methods, the combination of PDT and
chemotherapy has great potential and may soon move beyond model organisms.
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Two dimensional
Soybean phospholipids
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Iron oxide nanoparticles
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Tetrabutylammonium hydroxide
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